NOTE: This order is nonprecedential.

United States Court of Appeals for the Federal Circuit

ALEXION PHARMACEUTICALS, INC., ALEXION PHARMA INTERNATIONAL OPERATIONS LTD.,

Plaintiffs-Appellants

 \mathbf{v} .

SAMSUNG BIOEPIS CO. LTD.,

Defendant-Appellee

2024-1829

Appeal from the United States District Court for the District of Delaware in No. 1:24-cv-00005-GBW, Judge Gregory Brian Williams.

ON MOTION

PER CURIAM.

ORDER

Alexion Pharmaceuticals, Inc. and Alexion Pharma International Operations Ltd. move, pursuant to Rule 8 of the Federal Rules of Appellate Procedure, for an injunction of marketing and sales by Samsung Bioepis Co. Ltd. of its SB12 biosimilar product.

2 ALEXION PHARMACEUTICALS, INC. v. SAMSUNG BIOEPIS CO. LTD.

Upon consideration thereof,

IT IS ORDERED THAT:

Samsung is directed to respond to the motion no later than seven days from the date of entry of this order. Any reply in support of the motion is due no later than three days thereafter.

FOR THE COURT

Jarrett B. Perlow

Clerk of Court

June 24, 2024 Date